EXHIBIT 99.1 NEWS Fonar Corporation For Immediate Release The Inventor of MR Scanning™ Contact: Daniel Culver An ISO 13485 Company Director of Communications Melville, New York 11747 E-mail: investor@fonar.com Phone: (631) 694-2929 www.fonar.com Fax: (631) 390-1772 MELVILLE, NEW YORK, February 13, 2026 - FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning™, reported today its financial results for the second quarter of fiscal 2026 which ended December 31, 2025. FONAR's primary source of income is a ...

Financial Performance - For the six-month period ended December 31, 2025, the company reported net income of $5.2 million on revenues of $51.6 million, compared to net income of $6.2 million on revenues of $50.0 million for the same period in 2024[144]. - Operating income decreased from $7.0 million for the six months ended December 31, 2024, to $6.2 million for the same period in 2025, while costs and expenses increased by 5.9% to $45.4 million[149]. - Consolidated net revenues increased by 3.3% to $51.6 million for the first six months of fiscal 2026, compared to $50.0 million for the same period in fiscal 2025[165]. - Total costs and expenses rose by 5.9% to $45.4 million in the first six months of fiscal 2026, up from $42.9 million in the first six months of fiscal 2025[165]. - Operating income decreased to $6.2 million in the first six months of fiscal 2026, down from $7.0 million in the same period of fiscal 2025[165]. Revenue Sources - Revenues from product sales and service and repair fees increased from $4.0 million for the first six months of fiscal 2025 to $4.9 million for the first six months of fiscal 2026[146]. - HMCA revenues increased by 1.6% to $46.7 million for the first six months of fiscal 2026, while the percentage of total revenues from this segment decreased slightly to 90.5%[154]. - Revenues from MRI product sales increased to $442,000 for the first six months of fiscal 2026 from $145,000 for the same period in fiscal 2025[161]. - Service and repair fees revenue increased to $4.5 million for the six-month period ended December 31, 2025, from $3.8 million for the same period in 2024[162]. Operational Challenges - Medicare reimbursement rates for MRI scans are flat year over year for calendar year 2026, creating operational challenges due to rising costs[160]. Cash Flow and Investments - Cash provided by operating activities was $1.9 million for the first six months of fiscal 2026, primarily due to net income of $5.2 million[173]. - Cash used in investing activities totaled $2.8 million for the first six months of fiscal 2026, including $2.3 million for property and equipment purchases[174]. Liabilities and Working Capital - Total liabilities decreased by 4.3% to $54.4 million at December 31, 2025, from $56.8 million at June 30, 2025[178]. - Working capital increased to $129.4 million at December 31, 2025, up from $127.5 million at June 30, 2025[180]. Future Plans - The company plans to open an additional location on Long Island, New York, with expected costs of approximately $900,000 for a new scanner and related buildout[184]. - The company believes its existing cash balances and internal cash generating capabilities are sufficient to finance capital expenditures and operations for at least the next 12 months[188]. Merger and Acquisition - The company is subject to customary restrictions on soliciting alternative acquisition proposals as part of the proposed going-private transaction[141]. - The proposed merger agreement includes a cash consideration of $19.00 per share for Common Stock and Class B Common Stock, and $6.34 per share for Class C Common Stock[139]. Research and Development - Research and development expenses increased by 31.0% to $895,000 for the first six months of fiscal 2026, compared to $683,000 for the same period in fiscal 2025[169]. Scans Performance - The aggregate number of scans performed by the sites owned and managed by the company increased to 109,952 scans from 106,168 scans in the first half of fiscal 2025[148].

Cash and cash equivalents decreased 6% to $53.0 million at December 31, 2025, as compared to $56.3 million for the fiscal year-ended June 30, 2025.Total Revenues - Net increased by 2% to $25.5 million for the quarter ended December 31, 2025, versus the corresponding quarter one year earlier. Total Revenues - Net increased by 3% to $51.6 million for the six-month period ended December 31, 2025, versus the corresponding six-month period one year earlier.Net Income increased 15% to $2.5 million for the quarte ...

Group 1 - The core issue is the investigation by Kaskela Law LLC into the proposed buyout of FONAR Corp. to assess whether the buyout price of $19.00 per share significantly undervalues the company's shares and disadvantages its investors [1][2][3] - FONAR announced the acquisition agreement on December 29, 2025, which will result in shareholders being cashed out and the company's shares ceasing to be publicly traded [2] - The investigation aims to determine if FONAR's investors are receiving adequate financial compensation for their shares and whether the company's officers or directors have breached their fiduciary duties or violated securities laws in the sale agreement [3]

Core Viewpoint - Levi & Korsinsky, LLP has initiated an investigation into potential breaches of fiduciary duty by the officers and directors of FONAR Corporation related to a management-led take-private merger approved in December 2025 [2]. Group 1 - The investigation focuses on whether the actions taken by FONAR's management and board were in violation of their fiduciary responsibilities [2]. - FONAR Corporation is publicly traded on NASDAQ under the ticker symbol FONR [1]. - Levi & Korsinsky, LLP is a nationally recognized law firm with expertise in securities litigation and has successfully recovered hundreds of millions of dollars for shareholders [3].

Merger Investigations - RAPT Therapeutics will be acquired by GlaxoSmithKline LLC for $58.00 per share, with an estimated aggregate equity value of $2.2 billion. The investigation focuses on whether the RAPT Board breached its fiduciary duties by failing to conduct a fair process and whether the deal provides fair value to shareholders [2] - Calavo Growers will be acquired by Mission Produce, Inc. for $27.00 per share, consisting of $14.85 in cash and 0.9790 shares of Mission for each share of Calavo, valuing Calavo at approximately $430 million. The investigation concerns potential breaches of fiduciary duties by the Calavo Board regarding the fairness of the deal [4] - Penumbra will be acquired by Boston Scientific Corporation in a cash and stock transaction valuing Penumbra at $374 per share, with an enterprise value of approximately $14.5 billion. The investigation examines whether the Penumbra Board failed to conduct a fair process and whether the deal consideration is fair [6] - FONAR Corporation will be acquired by FONAR, LLC and FONAR Acquisition Sub, Inc. for $19.00 per share in an all-cash transaction. The investigation looks into whether the FONAR Board breached its fiduciary duties by not ensuring a fair process and fair value for shareholders [8]

Group 1 - The last commentary on FONAR Corporation (FONR) was in September of the previous year, resulting in a downgrade of the company due to shares trading at $15.60, which subsequently fell below $14 [1] - The company specializes in magnetic resonance imaging (MRI) technology [1] Group 2 - The commentary reflects a strategy focused on investing in undervalued profitable stocks with strong balance sheets and minimal debt [1] - The approach includes writing calls against positions to generate additional income and managing risk through position sizing and trailing stop losses [1]

Core Viewpoint - Monteverde & Associates PC is investigating FONAR Corporation regarding its proposed sale to affiliates of CEO Timothy Damadian, questioning the fairness of the deal for shareholders [1]. Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions for shareholders [1]. - The firm is located in the Empire State Building, New York City, and specializes in class action securities litigation [2]. Transaction Details - Under the proposed transaction, FONAR's Class B common stockholders will receive $19.00 per share, while Class C common stockholders will receive $6.34 per share [1].

FDA Approvals & Rejections - ARS Pharma's neffy, a needle-free epinephrine nasal spray for emergency treatment of Type I allergic reactions, received approval in China, with commercial availability expected in spring 2026. The product generated $31.3 million in U.S. revenue in Q3 2025 [3][4]. - Vanda Pharmaceuticals' NEREUS, an oral NK-1 receptor antagonist for preventing motion-induced vomiting, received FDA approval, marking the first new treatment for motion sickness in over 40 years. The drug demonstrated a meaningful reduction in vomiting in clinical trials [5][6]. Clinical Trials - Breakthroughs & Setbacks - InflaRx's analyses from a halted Phase 3 trial of Vilobelimab in pyoderma gangrenosum indicated potential efficacy signals with longer treatment duration, prompting plans to discuss alternative endpoints with the FDA [15][17]. - SELLAS reported that survival in its Phase 3 REGAL trial for Galinpepimut-S (GPS) in acute myeloid leukaemia is extending longer than anticipated, potentially increasing the likelihood of a positive outcome [18][19]. - Ultragenyx announced that its Phase 3 studies for Setrusumab in Osteogenesis Imperfecta failed to meet primary endpoints, leading to a decline in investor confidence [20][21]. - Genmab decided to discontinue clinical development of Acasunlimab to focus on higher-priority programs, with no impact expected on its full-year 2025 financial guidance [22][23]. Corporate Actions - FONAR Corporation agreed to be taken private by a CEO-led acquisition group for $19.00 per share, valuing the transaction at a significant premium. The deal is expected to close in Q3 2026, subject to shareholder approval [12][13][14].

Market Overview - The U.S. stock market is closing 2025 on a cautious note, with major index futures edging lower, extending a three-session losing streak, and hopes for a year-end "Santa Claus" rally fading [1] - Despite the recent pullback, 2025 has been a remarkable year for equities, with the S&P 500 poised for its third consecutive year of double-digit gains [1] Premarket Trading and Futures Movements - As of early Wednesday, U.S. stock futures indicated a softer open, with Nasdaq 100 futures down 0.43%, S&P 500 futures down 0.28%, and Dow Jones futures down 0.14% [2] - The S&P 500, Nasdaq Composite, and Dow Jones all finished slightly lower on Tuesday, marking the third consecutive day of losses [2] Commodities Market - Crude oil futures were trading lower by 0.38%, around $57.72 per barrel, while Gold Spot was down 0.35% to approximately $4,324.59 per ounce [3] Major Market Indexes Performance - The S&P 500 is on track for an annual gain of 17-18%, the Dow Jones has advanced 13-14%, and the Nasdaq Composite has jumped nearly 21% in 2025 [4] - This performance marks the S&P 500's third consecutive year of double-digit returns, a rare achievement since the 1940s [4] Federal Reserve Outlook - The Federal Reserve is expected to cut rates in 2026, with uncertainty regarding the extent and pace due to internal divisions and mixed economic data [6] - The FOMC approved a quarter-point reduction in December 2025, bringing the main interest rate to a range between 3.5% and 3.75% [6] - Inflation remains above the Fed's 2% target, with unemployment rising to 4.6% in November and only 64,000 jobs added [6] Corporate Developments - Vanda Pharmaceuticals shares surged over 18% after receiving FDA approval for its drug NEREUS [13] - Nike shares rose 1.54% following CEO Elliott Hill's purchase of approximately $1 million in company shares [13] - Nvidia's stock surged approximately 180% in 2025, driven by robust demand for AI chips, with ByteDance planning to increase spending on Nvidia's AI chips to around $14 billion in 2026 [13] - Urgent.ly Inc. shares rose significantly after the adjournment of its annual stockholder meeting [13] - Applied Digital announced a proposed merger with EKSO Bionics, leading to a 40% surge in EKSO shares [13] - FONAR Corporation shares surged 28.4% after confirming its acquisition by an insider-led group [13] - Society Pass Incorporated shares jumped 16.4% following a newly priced public offering [13] - Palantir and Tesla saw their shares decline amidst concerns about technology giants' capital expenditures [13] - Boeing shares advanced 0.6% after being awarded an $8.58 billion contract by the Defense Department [13] - Meta Platforms shares ended up 1.1% following its acquisition of an AI startup for over $2 billion [13]